Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Cohort of Patients with Type 2 Diabetes Mellitus Undergoing Phlebotomy at an Endocrinology Clinic
- 1,
- 1,2*,
- 3,
- 3,
- 4,
- 5
- 1Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy, Universiti Teknologi Mara (UiTM), Bandar Puncak Alam, Selangor, Malaysia.
- 2Institute for Big Data Analytics and Artificial Intelligence (IBDAAI), Kompleks Al-Khawarizmi, Universiti Teknologi MARA, Shah Alam, Selangor, Malaysia.
- 3Faculty of Medicine, UiTM Selangor Branch Sungai Buloh Campus, Sungai Buloh, Selangor, Malaysia.
- 4Department of Biosciences, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India.
- 5Pharmacy Practice Department, College of Pharmacy, Qassim University, Qassim University Medical City, Saudi Arabia.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Mathumalar Loganathan Fahrni
Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy, Universiti Teknologi Mara (UiTM), Bandar Puncak Alam, Selangor, Malaysia.; Institute for Big Data Analytics and Artificial Intelligence (IBDAAI), Kompleks Al-Khawarizmi, Universiti Teknologi MARA, Shah Alam, Selangor, Malaysia.
Email: mathumalar@gmail.com
Copyright: © 2024 The Author(s). This is an open access article.
Published: Jan 1, 2024, Received: May 20, 2024, Accepted: Jun 12, 2024
Abstract
Background: Statin-associated muscle symptoms (SAMS), the commonest statin-induced adverse effects, could hinder patient adherence and possibly lead to discontinuation of therapy, which then increases patients’ risks for developing cardiovascular events. Although statins are the most frequently prescribed lipid-lowering medication, the occurrence and severity of SAMS among the Malaysian population are less known. Objectives: To examine the likelihood and types of muscle symptoms attributable to statins, and the risk factors for developing the symptoms among statins users. Materials and Methods: This was a cross-sectional study conducted with convenience sampling of patients with type 2 diabetes mellitus undergoing phlebotomy at an endocrinology clinic of a secondary hospital in a suburban city. Demographic and clinical data for the evidence of SAMS were retrieved from the hospital information system. A total of 214 patients were screened, and 50 subjects were recruited for interviews based on the study’s inclusion and exclusion criteria. Muscle symptoms that were evident through clinician notes, and self-reported signs and symptoms by patients during the interview were assessed to determine whether they were SAMS or not. This was done using a pre-structured published questionnaire via patient interview, and the likelihood was then determined using the SAMS-clinical index (SAMS-CI) tool. Results: In this cohort, the probability of having had a statin-associated muscle adverse event was 0.48, i.e., 48% “probable” and “possible” likelihood of SAMS having occurred for a patient who consumed a statin. The mean SAMS-CI score was 6.32 ± 0.470 (±7.4%) [CI: 5.85–6.79], which fell under an “unlikely” category. The most frequent type of muscle symptom was myalgia, which was experienced as muscle aches, stiffness, cramps, symptoms worsening after exercise, muscle tenderness, and trouble moving knees or arm joints. These symptoms were proximal and symmetrical in nature and commonly involved large muscle groups such as the thighs, buttocks, calves, and back muscles. An elevation in creatinine kinase was not commonly observed. Conclusion: A minority (6%) of the patients that we sampled experienced SAMS, which were probably attributable to statins. Nevertheless, caution must be exercised for female patients with a familial history of heart disease being prescribed with the lipophilic statins, atorvastatin, and simvastatin, and those who report aches in the large muscle groups.
Keywords
Subject
Recommended articles
- Identification of risk factors for carbamazepine‑induced serious mucocutaneous adverse reactions: A case‑control study using data from spontaneous adverse drug reaction reports
Ilma Bertulyte, Sofie Schwan, Pär Hallberg · Journal of Pharmacology and Pharmacotherapeutics
- The safety of ketoprofen in different ages
Claudia Carbone, Pierandrea Rende, Pasquale Comberiati · Journal of Pharmacology and Pharmacotherapeutics
- Retrospective evaluation of adverse drug reactions induced by antihypertensive treatment
Pierandrea Rende, Laura Paletta, Giuseppe Gallelli · Journal of Pharmacology and Pharmacotherapeutics
- Clinical and economic burden of adverse drug reactions
Janet Sultana, Paola Cutroneo, Gianluca Trifirò · Journal of Pharmacology and Pharmacotherapeutics
- Pharmacovigilance and the Italian Medicines Agency
Giuseppe Pimpinella, Loriana Tartaglia · Journal of Pharmacology and Pharmacotherapeutics
- Vertigo/dizziness as a Drugs’ adverse reaction
Serafina Chimirri, Rossana Aiello, Carmela Mazzitello · Journal of Pharmacology and Pharmacotherapeutics
Readers Also Viewed
Pharmacogenomics Meets Generative AI: Transforming Clinical Trial Design with Large Language Models
Annisa Fatharani, Ali Alsayegh
Jan 1, 2026
Knowledge, Attitude, and Practice on Digital Eye Strain Among Healthcare Students at a Private University in Northern Peninsular Malaysia
Lim Chin Hung, Subramani Parasuraman, Sam Aaseer Thamby
Jan 1, 2026
Clinical Outcomes and Management of Post-varicocelectomy on Male Fertility: A Comprehensive Review
Mohammad Akbar Hossain
Jan 1, 2026